AtriCure(NASDAQ) ATRC

Current Price$34.99

Market Cap$1.77B

Since IPO (2005)+149%

5 Year-56%

1 Year+16%

1 Month+24%

AtriCure last closing stock price
Metric	Price	Date
Last close	USD 35.04	2026-07-24

AtriCure stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.26%	USD 34.95	2026-07-17
1 month	+23.9%	USD 28.28	2026-06-24
3 month	+19.67%	USD 29.28	2026-04-24
Year to date	-11.43%	USD 39.56	2025-12-31
1 year	+16.14%	USD 30.17	2025-07-24
3 year	-34.12%	USD 53.19	2023-07-25
5 year	-56.29%	USD 80.17	2021-07-23
Since inception	+148.86%	USD 14.08	2005-08-05

AtriCure Financials at a Glance

Market Cap

$1.77B

Revenue (TTM)

$569.62M

Net Income (TTM)

$10.55M

EPS (TTM)

$0.22

P/E Ratio

161.85

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$34.99

Volume

1,655,002.066

Open

$33.69

Price

$34.99

Volume

1,655,002.066

Open

$33.69

Previous Close

$35.04

Daily Range

$32.41 - $35.34

52-Week Range

$25.36 - $43.18

Estimated Earnings Date

Nov 4, 2026

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$34.99

Volume

1,655,002.066

Open

$33.69

Previous Close

$35.04

Daily Range

$32.41 - $35.34

52-Week Range

$25.36 - $43.18

Estimated Earnings Date

Nov 4, 2026

ATRC News

What to Expect from AtriCure

Seth JaysonJul 29, 2013

Page 1

ATRC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AtriCure

AtriCure makes tools to fix irregular heartbeats and manage pain. These devices help doctors treat patients with serious heart conditions. The products help people recover faster after major surgery.

Tools for the Operating Room

Tissue Ablation: Handheld tools using heat or cold to scar heart tissue and stop irregular electrical signals.
Appendage Management: Mechanical implants that close off a small pouch in the heart to lower stroke risk.
Pain Management: Probes that freeze intercostal nerves during surgery to block pain for up to 90 days.
Hybrid AF Therapy: A combined procedure using surgical tools and catheters to treat advanced heart rhythm issues.

Recent Milestones and Trials

Launched the cryoXT probe in September 2025 to manage pain for amputation patients.
Enrolled the first patient in the BoxX-NoAF trial in October 2025 to study heart rhythm prevention.
Completed enrollment for the LeAAPS stroke reduction trial in July 2025 with 6,573 patients.
Released the AtriClip PRO-Mini in early 2025 to help surgeons during minimally invasive heart procedures.

Why Surgeons Choose AtriCure

AtriCure maintains direct sales teams in the United States, United Kingdom, and Australia to support medical centers. The company also uses synthetic training models to help physicians learn safe and effective surgical techniques.

The Latest Financial Numbers

Quarterly revenue reached $140.5 million in Q4 2025, a 13.1% increase year-over-year.
Operating income turned positive at $3.5 million in Q4 2025, improving from a $14.5 million loss.
Net income hit $1.8 million in Q4 2025, up 111.3% from the same period in 2024.
Free cash flow reached $23.4 million in Q4 2025, compared to negative $8.9 million previously.
Operating cash flow grew to $20 million in Q4 2025, up 243.2% from the prior year.

Bottom Line

AtriCure has moved from a niche heart device maker to a broader provider of rhythm and pain solutions. Its transition to profitability and focus on clinical trials show a maturing business model.

AI Generated • May 1, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,350

CEO

Michael H. Carrel, MBA

Website

www.atricure.com

Headquarters

Mason, OH 45040, US

ATRC Financials

Key Financial Metrics (TTM)

Gross Margin

76.16%

Operating Margin

2.44%

Net Income Margin

1.85%

Return on Equity

2.14%

Return on Capital

-0.59%

Return on Assets

1.56%

Earnings Yield

0.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.77B

Shares Outstanding

50.64M

Volume

1.66M

Avg. Volume

930.63K

Financials (TTM)

Gross Profit

$433.85M

Operating Income

$13.89M

EBITDA

$27.15M

Operating Cash Flow

$64.36M

Capital Expenditure

-$10.72M

Free Cash Flow

$53.64M

Cash & ST Invst.

$167.79M

Total Debt

$71.05M

AtriCure Performance Analysis

AtriCure annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 330,379,000	20.4%
2023	2023-12-31	USD 399,245,000	20.8%
2024	2024-12-31	USD 465,307,000	16.5%
2025	2025-12-31	USD 534,528,000	14.9%

AtriCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-1.4%
Q4	2025-12-31	4.6%
Q1	2026-03-31	0.5%
Q2	2026-06-30	8.7%

AtriCure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.02	N/A
2023	2023-12-31	USD -0.66	-35.3%
2024	2024-12-31	USD -0.95	44.8%
2025	2025-12-31	USD -0.24	-74.8%

AtriCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	95.7%
Q4	2025-12-31	735.7%
Q1	2026-03-31	-93.8%
Q2	2026-06-30	8081.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$153.60M

+12.8%

Gross Profit

$118.63M

+16.9%

Gross Margin

77.23%

N/A

Market Cap

$1.77B

N/A

Market Cap/Employee

$1.31M

N/A

Employees

1,350

N/A

Net Income

$8.96M

+244.7%

EBITDA

$3.18M

+335.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$167.79M

+42.4%

Total Debt

$71.05M

-8.0%

Accounts Receivable

$79.98M

+21.2%

Inventory

$83.93M

+9.9%

Long Term Debt

$71.05M

-4.4%

Short Term Debt

$0.00

-100.0%

Return on Assets

1.56%

N/A

Return on Invested Capital

2.34%

N/A

Free Cash Flow

-$7.85M

+40.6%

Operating Cash Flow

-$4.00M

+63.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$35.00-1.44%

NVCRNovocure Ltd

NVCRNovocure Ltd$17.65-11.71%

SEMSelect Medical Holdings Corporation

SEMSelect Medical Holdings Corporation$16.51-0.09%

BLFSBioLife Solutions, Inc.

BLFSBioLife Solutions, Inc.$29.98-2.57%

XERSXeris Biopharma Holdings, Inc.

XERSXeris Biopharma Holdings, Inc.$8.32-1.07%

LMATLeMaitre Vascular, Inc.

LMATLeMaitre Vascular, Inc.$95.59-1.95%

AZTAAzenta, Inc.

AZTAAzenta, Inc.$27.37-3.29%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

STAKStak

STAKStak$9.27+6.02%

PATHUiPath

PATHUiPath$10.84+0.06%

Questions About ATRC

What is the current price of AtriCure?

AtriCure is trading at $35.04 per share.

What is the 52-week range for AtriCure?

Over the past 52 weeks, AtriCure has traded between $25.36 and $43.18.

How much debt does AtriCure have?

As of the most recent reporting period, AtriCure reported total debt of $71.05M.

How much cash does AtriCure have on hand?

AtriCure reported $167.79M in cash and cash equivalents in its most recent financial results.

What is AtriCure’s dividend yield?

AtriCure does not currently have a dividend yield.

AtriCure(NASDAQ) ATRC

AtriCure Financials at a Glance

ATRC News

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

AtriCure (ATRC) Q2 Revenue Jumps 17%

Why Chefs' Warehouse, SMART Global Holdings, and AtriCure Jumped Today

Here's Why ArtiCure, Inc. Is Up Double-Digits Today

Why AtriCure, Inc. Shares Surged

Why AtriCure Inc. Shares Jumped

What to Expect from AtriCure

ATRC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AtriCure

Tools for the Operating Room

Recent Milestones and Trials

Why Surgeons Choose AtriCure

The Latest Financial Numbers

Bottom Line

ATRC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AtriCure Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ATRC

What is the current price of AtriCure?

What is the 52-week range for AtriCure?

How much debt does AtriCure have?

How much cash does AtriCure have on hand?

What is AtriCure’s dividend yield?

Premium Investing Services